Document is current

Article History

Accepted: 23 April 2023

First Online: 29 May 2023

Declarations

:

: This trial was financially funded by the company of SinoCellTech Ltd. (Beijing, China).

: Dr. Liangzhi Xie is employee of Sinocelltech Ltd. and has ownership or potential stock option interests in the company. All authors declare no other conflicts of interest.

: The final study protocol was approved by the ethics committee of the First Affiliated Hospital, Zhejiang University School of Medicine (approval NO. 2017-EC-244). All procedures involving subjects were strictly carried out according to Helsinki Declaration, the national Good Clinical Practice (GCP), the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), and all applicable regulatory requirements and laws. Before any procedures were performed, subjects signed written informed permission and were allowed to withdraw from the study at any moment.

: Not applicable.

: Not applicable.

: The original information in this article that supports the study conclusions is publicly available. All reasonable inquiries related to this study are welcomed.

: Not applicable.

: Jianzhong Shentu and Liangzhi Xie were involved in the study’s conception, design, and planning. Guolan Wu, Huili Zhou, Chang Xu, Lihua Wu, and Jingjing Zhang were all involved in the clinical trial’s execution, data collection, and interpretation. Duo Lv was in charge of the research project’s quality control. Jing Wu and Guolan Wu were responsible for data analysis, findings interpretation, and manuscript drafting. All authors have reviewed the manuscript substantially and agreed to submit the final version.